Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
Barrett JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, Cannon J, Poultsides GA, Rocha F, Crown A, Beal E, Michael Pawlik T, Fields R, Panni RZ, Smith P, Idrees K, Cho C, Beems M, Maithel S, Weber S, Erik Abbott D.
Barrett JR, et al. Among authors: crown a.
J Surg Oncol. 2020 Jun;121(7):1067-1073. doi: 10.1002/jso.25896. Epub 2020 Mar 9.
J Surg Oncol. 2020.
PMID: 32153032
Free PMC article.